<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989261</url>
  </required_header>
  <id_info>
    <org_study_id>AC220-002</org_study_id>
    <secondary_id>2009-013093-41</secondary_id>
    <nct_id>NCT00989261</nct_id>
  </id_info>
  <brief_title>Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)</brief_title>
  <acronym>ACE</acronym>
  <official_title>Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AC220 will be administered as a once daily oral solution given continuously as 28-day
      treatment cycles, without any rest periods, until disease progression, relapse, intolerance
      to the drug, or elective allogeneic hematopoietic stem cell transplantation (HSCT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 31, 2014</completion_date>
  <primary_completion_date type="Actual">September 28, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [+] Participants)</measure>
    <time_frame>Within the first 3 cycles of treatment (84 days)</time_frame>
    <description>Derived disease assessment based on local morphology of bone marrow disease performed by each local site pathologist, including all on-treatment data (Safety Population, FLT3-ITD[+] Participants)
Modified from Cheson et al, abbreviations include the following: CR=complete remission; CRc=composite complete remission (CR+CRp+CRi); CRi=complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia=all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia &lt;1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib=All criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion; CRp=complete remission with incomplete platelet recovery; NR=no response; PR=partial remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [-] Participants)</measure>
    <time_frame>Within the first 3 cycles of treatment (84 days)</time_frame>
    <description>Derived disease assessment based on local morphology of bone marrow disease performed by each local site pathologist, including all on-treatment data (Safety Population, FLT3-ITD[-] Participants)
Modified from Cheson et al, abbreviations include the following: CR=complete remission; CRc=composite complete remission (CR+CRp+CRi); CRi=complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia=all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia &lt;1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib=All criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion; CRp=complete remission with incomplete platelet recovery; NR=no response; PR=partial remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Composite Complete Remission (CRc), Categorised by FLT3-ITD Status</measure>
    <time_frame>within 28 months</time_frame>
    <description>CRc is defined as composite complete remission (CR+CRp+CRi) - CR = complete remission; CRp = complete remission with incomplete platelet recovery; CRi = complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia = all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia &lt;1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib = all criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Composite Complete Remission in FLT3-ITD (+) Participants Who Achieved CRc Based on All On-Treatment Data</measure>
    <time_frame>From time at which CRc was achieved until disease progression or death, up to approximately 3 years post treatment</time_frame>
    <description>Kaplan-Meier analysis of duration of composite complete remission derived based on local morphology including all on-treatment data (Safety Population).
The definition of relapse at CRc includes an evaluation of blasts in the peripheral blood of &gt;1%.Though not specified in the protocol, the addition of these criteria was deemed necessary for consistency with the Cheson criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Composite Complete Remission in FLT3-ITD (-) Participants Who Achieved CRc Based on All On-Treatment Data</measure>
    <time_frame>From time at which CRc was achieved until disease progression or death, up to approximately 3 years post treatment</time_frame>
    <description>Kaplan-Meier analysis of duration of composite complete remission derived based on local morphology including all on-treatment data (Safety Population).
The definition of relapse at CRc includes an evaluation of blasts in the peripheral blood of &gt;1%.Though not specified in the protocol, the addition of these criteria was deemed necessary for consistency with the Cheson criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Response in FLT3-ITD (+) Participants</measure>
    <time_frame>From the time of any response until disease progression or death, up to approximately 3 years post treatment</time_frame>
    <description>Kaplan-Meier analysis of duration of any response (CR, CRp, CRi, or PR), derived based on local morphology for participants who achieved a response during the first 3 cycles of treatment (Safety Population).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Response in FLT3-ITD (-) Participants</measure>
    <time_frame>From the time of any response until disease progression or death, up to approximately 3 years post treatment</time_frame>
    <description>Kaplan-Meier analysis of duration of any response (CR, CRp, CRi, or PR), derived based on local morphology for participants who achieved a response during the first 3 cycles of treatment (Safety Population).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Leukemia-free Survival in FLT3-ITD (+) Participants</measure>
    <time_frame>From the time CRc was achieved until disease progression or death, up to approximately 3 years post treatment</time_frame>
    <description>Kaplan-Meier analysis of leukemia-free survival in participants who achieved a CRc in the first three cycles of treatment derived based on local morphology (Safety Population).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Leukemia-free Survival in FLT3-ITD (-) Participants</measure>
    <time_frame>From the time CRc was achieved until disease progression or death, up to approximately 3 years post treatment</time_frame>
    <description>Kaplan-Meier analysis of leukemia-free survival in participants who achieved a CRc in the first three cycles of treatment derived based on local morphology (Safety Population).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Overall Survival in FLT3-ITD (+) Participants</measure>
    <time_frame>Time from first dose to death from any cause, up to 3 years post treatment</time_frame>
    <description>Kaplan-Meier analysis of overall survival (Safety Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Overall Survival in FLT3-ITD (-) Participants</measure>
    <time_frame>Time from first dose to death from any cause, up to approximately 3 years post treatment</time_frame>
    <description>Kaplan-Meier analysis of overall survival (Safety Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Treatment-related Death</measure>
    <time_frame>Within first 3 cycles of treatment (84 days)</time_frame>
    <description>Early treatment-related deaths included all treatment-related deaths prior to the end of Cycle 3 with a 3-day window (Cycle 3 end date + 3 days), unless the death was following a CRc response assessed by the Investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1; ≥60 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2; ≥18 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound AC220</intervention_name>
    <description>Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.</description>
    <arm_group_label>Cohort 1; ≥60 years of age</arm_group_label>
    <arm_group_label>Cohort 2; ≥18 years of age</arm_group_label>
    <other_name>AC010220 × 2HCl, oral powder for reconstitution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Current enrollment is open only to FLT3-ITD positive, Cohort 1.

        Inclusion Criteria:

          1. Males and females age ≥18 years in second relapse or refractory.

          2. Males and females age ≥60 years in first relapse or refractory.

          3. Must have baseline bone marrow sample taken.

          4. Morphologically documented primary AML or AML secondary to myelodysplastic syndrome
             (MDS with ≥20% bone marrow or peripheral blasts), as defined by the World Health
             Organization (WHO) criteria, confirmed by pathology review at treating institution.

          5. Able to swallow the liquid study drug.

          6. Eastern Cooperative Oncology Group performance status of 0 to 2

          7. In the absence of rapidly progressing disease, the interval from prior treatment to
             time of AC220 administration will be at least 2 weeks for cytotoxic agents or at least
             5 half-lives for noncytotoxic agents. The use of chemotherapeutic or antileukemic
             agents other than hydroxyurea is not permitted during the study with the possible
             exception of intrathecal (IT) therapy at the discretion of the Investigator and with
             the agreement of the Sponsor.

          8. Persistent chronic clinically significant non-hematological toxicities from prior
             treatment must be ≤Grade 1.

          9. Prior therapy with FLT3 inhibitors is permitted, except previous treatment with AC220.

         10. Serum creatinine ≤1.5 × upper limit of normal (ULN) and glomerular filtration rate
             (GFR) &gt; 30 mL/min

         11. Serum potassium, magnesium, and calcium levels should be at least within institutional
             normal limits.

         12. Total serum bilirubin ≤1.5 × ULN

         13. Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤2.5 × ULN

         14. Females of childbearing potential must have a negative pregnancy test (urine β-hCG).

         15. Females of childbearing potential and sexually mature males must agree to use a
             medically accepted method of contraception throughout the study.

         16. Written informed consent must be provided.

        Exclusion Criteria:

          1. Patients over the age of 85 years except at the discretion of the Investigator and
             with agreement of the Sponsor.

          2. Diagnosis of acute promyelocytic leukemia

          3. Diagnosis of chronic myelogenous leukemia (CML) in blast crisis

          4. AML in relapse or refractory after 3 or more previous lines of chemotherapy (and/or
             HSCT) treatment

          5. AML or antecedent MDS secondary to prior chemotherapy

          6. Persistent clinically significant non-hematological toxicity that is Grade &gt;1 by NCI
             CTCAE v4 from prior chemotherapy

          7. Patients who have had HSCT and are within 100 days of transplant and/or are still
             taking immunosuppressive drugs and/or have clinically significant graft-versus-host
             disease requiring treatment and/or have &gt;Grade 1 persistent non hematological toxicity
             related to the transplant

          8. Clinically active central nervous system (CNS) leukemia. Patients with CNS leukemia,
             which is controlled, but who are still receiving IT therapy at study entry may be
             considered eligible and continue receive IT therapy at the discretion of the
             Investigator and with agreement of the Sponsor.

          9. Patients who have previously received AC220

         10. Disseminated intravascular coagulation (DIC) (diagnosis by laboratory or clinical
             assessment)

         11. Major surgery within 4 weeks prior to enrollment in the study

         12. Radiation therapy within 4 weeks prior to, or concurrent with study

         13. Use of concomitant drugs that prolong the time between the start of the Q wave and the
             end of the T wave (QT)/corrected interval between the Q wave and T wave (QTc) interval
             and/or are CYP3A4 inhibitors are prohibited with the exception of antibiotics,
             antifungals, and other antimicrobials that are used as standard of care to prevent or
             treat infections and other such drugs that are considered absolutely essential for the
             care of the patient.

         14. Uncontrolled or significant cardiovascular disease

         15. Women who are pregnant, lactating, or unwilling to use contraception if of
             childbearing potential

         16. Men who are unwilling to use contraception if their partners are of childbearing
             potential

         17. Active, uncontrolled infection

         18. Human immunodeficiency virus positivity

         19. Active hepatitis B or C or other active liver disease

         20. History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the
             possible exception of patients in complete remission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Interim Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Ambit Biosciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vanderbuilt Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes Centre Regional de Lutte Contre le Cancer</name>
      <address>
        <city>Marseille</city>
        <state>Cedex 9</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologie - CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Angers</name>
      <address>
        <city>d'Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henry Becquerel, Service d'Hematologie</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire, Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>5311</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unikliniksklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Essen, Westdeutsches Tumorzentrum</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe Universitat</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig Selbstandige Abteilung fur Hamatologie</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universitat Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universitat Munchen</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munster</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Regensburg Abteilung fur Hamatologie</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus GmbH</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Di Ematologia &quot;L.Ea. Seragnoli&quot;</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unita Trapianti di Midollo Osseo per Adulti</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero &quot;A. Businco&quot; - Centro di Riferimento Oncologico Regionale</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Universitaria Vittorio Emanuele-Ferrarotto</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmacia Ospidaliera</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile S. Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant Eugenio</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi di Roma Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine, Clinica Ematologica</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utrecht University Medical Centre, Dept. of Hematology</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnoslaskie Centrum Transplantacji Komorkowych z</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia del Hospital Universitari Germans</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia-Hospital Universitari de Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Princesa, Servicio de Hematologia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca, Hospital Clinico, Servicio de Hematologia</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe, Servicio de Hematologia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrook's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <zip>HU 16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint James University Hospital, Institute of Oncology</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanmmersmith Hospital, Dept. of Hematology</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2009</study_first_posted>
  <results_first_submitted>September 25, 2019</results_first_submitted>
  <results_first_submitted_qc>November 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2019</results_first_posted>
  <disposition_first_submitted>September 30, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 3, 2016</disposition_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>AC220</keyword>
  <keyword>acute</keyword>
  <keyword>FLT3</keyword>
  <keyword>inhibitor</keyword>
  <keyword>kinase</keyword>
  <keyword>leukemia</keyword>
  <keyword>leukaemia</keyword>
  <keyword>myeloid</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 333 participants from 9 countries (United States, Germany, France, Italy, United Kingdom, Spain, Netherlands, Canada, and Poland) who met all inclusion and none of the exclusion criteria were included in the study.</recruitment_details>
      <pre_assignment_details>All participants in both cohorts initially received a starting dose of 200 mg/day quizartinib (maximum tolerated dose). To ensure complete inhibition of FLT3, all male subjects in both cohorts later received a starting dose of 135 mg/day quizartinib, and all females received a starting dose of 90 mg/day.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1; ≥60 Years of Age</title>
          <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2; ≥18 Years of Age</title>
          <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Still in follow up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1; ≥60 Years of Age</title>
          <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2; ≥18 Years of Age</title>
          <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="157"/>
            <count group_id="B2" value="176"/>
            <count group_id="B3" value="333"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" lower_limit="32" upper_limit="86"/>
                    <measurement group_id="B2" value="51.0" lower_limit="19" upper_limit="77"/>
                    <measurement group_id="B3" value="63.0" lower_limit="19" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Less than 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="276"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.66" spread="14.75"/>
                    <measurement group_id="B2" value="74.76" spread="19.41"/>
                    <measurement group_id="B3" value="74.72" spread="17.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [+] Participants)</title>
        <description>Derived disease assessment based on local morphology of bone marrow disease performed by each local site pathologist, including all on-treatment data (Safety Population, FLT3-ITD[+] Participants)
Modified from Cheson et al, abbreviations include the following: CR=complete remission; CRc=composite complete remission (CR+CRp+CRi); CRi=complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia=all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia &lt;1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib=All criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion; CRp=complete remission with incomplete platelet recovery; NR=no response; PR=partial remission.</description>
        <time_frame>Within the first 3 cycles of treatment (84 days)</time_frame>
        <population>Derived disease assessments were conducted in the Safety Population (FLT3-ITD [+] participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [+] Participants)</title>
          <description>Derived disease assessment based on local morphology of bone marrow disease performed by each local site pathologist, including all on-treatment data (Safety Population, FLT3-ITD[+] Participants)
Modified from Cheson et al, abbreviations include the following: CR=complete remission; CRc=composite complete remission (CR+CRp+CRi); CRi=complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia=all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia &lt;1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib=All criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion; CRp=complete remission with incomplete platelet recovery; NR=no response; PR=partial remission.</description>
          <population>Derived disease assessments were conducted in the Safety Population (FLT3-ITD [+] participants).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite complete remission (CRc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete remission (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete remission with incomplete platelet (CRp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete remission with incomplete hematologic CRi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial remission (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response (NR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [-] Participants)</title>
        <description>Derived disease assessment based on local morphology of bone marrow disease performed by each local site pathologist, including all on-treatment data (Safety Population, FLT3-ITD[-] Participants)
Modified from Cheson et al, abbreviations include the following: CR=complete remission; CRc=composite complete remission (CR+CRp+CRi); CRi=complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia=all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia &lt;1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib=All criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion; CRp=complete remission with incomplete platelet recovery; NR=no response; PR=partial remission.</description>
        <time_frame>Within the first 3 cycles of treatment (84 days)</time_frame>
        <population>Derived disease assessments were conducted in the Safety Population (FLT3-ITD [-] participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [-] Participants)</title>
          <description>Derived disease assessment based on local morphology of bone marrow disease performed by each local site pathologist, including all on-treatment data (Safety Population, FLT3-ITD[-] Participants)
Modified from Cheson et al, abbreviations include the following: CR=complete remission; CRc=composite complete remission (CR+CRp+CRi); CRi=complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia=all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia &lt;1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib=All criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion; CRp=complete remission with incomplete platelet recovery; NR=no response; PR=partial remission.</description>
          <population>Derived disease assessments were conducted in the Safety Population (FLT3-ITD [-] participants).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite complete remission (CRc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete remission (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete remission with incomplete platelet (CRp)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete remission with incomplete hematologic CRi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial remission (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response (NR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite Complete Remission (CRc), Categorised by FLT3-ITD Status</title>
        <description>CRc is defined as composite complete remission (CR+CRp+CRi) - CR = complete remission; CRp = complete remission with incomplete platelet recovery; CRi = complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia = all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia &lt;1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib = all criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion.</description>
        <time_frame>within 28 months</time_frame>
        <population>Composite complete remission was assessed in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Complete Remission (CRc), Categorised by FLT3-ITD Status</title>
          <description>CRc is defined as composite complete remission (CR+CRp+CRi) - CR = complete remission; CRp = complete remission with incomplete platelet recovery; CRi = complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia = all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia &lt;1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib = all criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion.</description>
          <population>Composite complete remission was assessed in the Safety Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FLT3-ITD(+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLT3-ITD(-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Composite Complete Remission in FLT3-ITD (+) Participants Who Achieved CRc Based on All On-Treatment Data</title>
        <description>Kaplan-Meier analysis of duration of composite complete remission derived based on local morphology including all on-treatment data (Safety Population).
The definition of relapse at CRc includes an evaluation of blasts in the peripheral blood of &gt;1%.Though not specified in the protocol, the addition of these criteria was deemed necessary for consistency with the Cheson criteria.</description>
        <time_frame>From time at which CRc was achieved until disease progression or death, up to approximately 3 years post treatment</time_frame>
        <population>Duration of composite complete remission was assessed in the Safety Population based on FLT3-ITD (+) participants available for this analysis (Cohort 1: n=63; Cohort 2: n=62).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Composite Complete Remission in FLT3-ITD (+) Participants Who Achieved CRc Based on All On-Treatment Data</title>
          <description>Kaplan-Meier analysis of duration of composite complete remission derived based on local morphology including all on-treatment data (Safety Population).
The definition of relapse at CRc includes an evaluation of blasts in the peripheral blood of &gt;1%.Though not specified in the protocol, the addition of these criteria was deemed necessary for consistency with the Cheson criteria.</description>
          <population>Duration of composite complete remission was assessed in the Safety Population based on FLT3-ITD (+) participants available for this analysis (Cohort 1: n=63; Cohort 2: n=62).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="6.3" upper_limit="15.7"/>
                    <measurement group_id="O2" value="10.6" lower_limit="8.1" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Composite Complete Remission in FLT3-ITD (-) Participants Who Achieved CRc Based on All On-Treatment Data</title>
        <description>Kaplan-Meier analysis of duration of composite complete remission derived based on local morphology including all on-treatment data (Safety Population).
The definition of relapse at CRc includes an evaluation of blasts in the peripheral blood of &gt;1%.Though not specified in the protocol, the addition of these criteria was deemed necessary for consistency with the Cheson criteria.</description>
        <time_frame>From time at which CRc was achieved until disease progression or death, up to approximately 3 years post treatment</time_frame>
        <population>Duration of composite complete remission was assessed in the Safety Population based on FLT3-ITD (-) participants available for this analysis (Cohort 1: n=16; Cohort 2: n=12).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Composite Complete Remission in FLT3-ITD (-) Participants Who Achieved CRc Based on All On-Treatment Data</title>
          <description>Kaplan-Meier analysis of duration of composite complete remission derived based on local morphology including all on-treatment data (Safety Population).
The definition of relapse at CRc includes an evaluation of blasts in the peripheral blood of &gt;1%.Though not specified in the protocol, the addition of these criteria was deemed necessary for consistency with the Cheson criteria.</description>
          <population>Duration of composite complete remission was assessed in the Safety Population based on FLT3-ITD (-) participants available for this analysis (Cohort 1: n=16; Cohort 2: n=12).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="8.1" upper_limit="30.4"/>
                    <measurement group_id="O2" value="7.0" lower_limit="4.1" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Any Response in FLT3-ITD (+) Participants</title>
        <description>Kaplan-Meier analysis of duration of any response (CR, CRp, CRi, or PR), derived based on local morphology for participants who achieved a response during the first 3 cycles of treatment (Safety Population).</description>
        <time_frame>From the time of any response until disease progression or death, up to approximately 3 years post treatment</time_frame>
        <population>Response (based on local morphology) was assessed in the Safety Population (FLT3-ITD [+] participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Any Response in FLT3-ITD (+) Participants</title>
          <description>Kaplan-Meier analysis of duration of any response (CR, CRp, CRi, or PR), derived based on local morphology for participants who achieved a response during the first 3 cycles of treatment (Safety Population).</description>
          <population>Response (based on local morphology) was assessed in the Safety Population (FLT3-ITD [+] participants).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="14.1" upper_limit="21.3"/>
                    <measurement group_id="O2" value="14.1" lower_limit="11.1" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Any Response in FLT3-ITD (-) Participants</title>
        <description>Kaplan-Meier analysis of duration of any response (CR, CRp, CRi, or PR), derived based on local morphology for participants who achieved a response during the first 3 cycles of treatment (Safety Population).</description>
        <time_frame>From the time of any response until disease progression or death, up to approximately 3 years post treatment</time_frame>
        <population>Response (based on local morphology) was assessed in the Safety Population (FLT3-ITD [-] participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Any Response in FLT3-ITD (-) Participants</title>
          <description>Kaplan-Meier analysis of duration of any response (CR, CRp, CRi, or PR), derived based on local morphology for participants who achieved a response during the first 3 cycles of treatment (Safety Population).</description>
          <population>Response (based on local morphology) was assessed in the Safety Population (FLT3-ITD [-] participants).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="10.1" upper_limit="34.1"/>
                    <measurement group_id="O2" value="8.1" lower_limit="7.4" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Leukemia-free Survival in FLT3-ITD (+) Participants</title>
        <description>Kaplan-Meier analysis of leukemia-free survival in participants who achieved a CRc in the first three cycles of treatment derived based on local morphology (Safety Population).</description>
        <time_frame>From the time CRc was achieved until disease progression or death, up to approximately 3 years post treatment</time_frame>
        <population>Leukemia-free survival (based on local morphology) was assessed in the Safety Population (FLT3-ITD [+] participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration of Leukemia-free Survival in FLT3-ITD (+) Participants</title>
          <description>Kaplan-Meier analysis of leukemia-free survival in participants who achieved a CRc in the first three cycles of treatment derived based on local morphology (Safety Population).</description>
          <population>Leukemia-free survival (based on local morphology) was assessed in the Safety Population (FLT3-ITD [+] participants).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="6.1" upper_limit="14.3"/>
                    <measurement group_id="O2" value="12.9" lower_limit="9.4" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Leukemia-free Survival in FLT3-ITD (-) Participants</title>
        <description>Kaplan-Meier analysis of leukemia-free survival in participants who achieved a CRc in the first three cycles of treatment derived based on local morphology (Safety Population).</description>
        <time_frame>From the time CRc was achieved until disease progression or death, up to approximately 3 years post treatment</time_frame>
        <population>Leukemia-free survival (based on local morphology) was assessed in the Safety Population (FLT3-ITD [-] participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration of Leukemia-free Survival in FLT3-ITD (-) Participants</title>
          <description>Kaplan-Meier analysis of leukemia-free survival in participants who achieved a CRc in the first three cycles of treatment derived based on local morphology (Safety Population).</description>
          <population>Leukemia-free survival (based on local morphology) was assessed in the Safety Population (FLT3-ITD [-] participants).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="8.1" upper_limit="26.1"/>
                    <measurement group_id="O2" value="7.0" lower_limit="5.0" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Overall Survival in FLT3-ITD (+) Participants</title>
        <description>Kaplan-Meier analysis of overall survival (Safety Population)</description>
        <time_frame>Time from first dose to death from any cause, up to 3 years post treatment</time_frame>
        <population>Overall survival was assessed in the Safety Population (FLT3-ITD [+] participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration of Overall Survival in FLT3-ITD (+) Participants</title>
          <description>Kaplan-Meier analysis of overall survival (Safety Population)</description>
          <population>Overall survival was assessed in the Safety Population (FLT3-ITD [+] participants).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" lower_limit="21.3" upper_limit="29.7"/>
                    <measurement group_id="O2" value="24.0" lower_limit="21.1" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Overall Survival in FLT3-ITD (-) Participants</title>
        <description>Kaplan-Meier analysis of overall survival (Safety Population)</description>
        <time_frame>Time from first dose to death from any cause, up to approximately 3 years post treatment</time_frame>
        <population>Overall survival was assessed in the Safety Population (FLT3-ITD [-] participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration of Overall Survival in FLT3-ITD (-) Participants</title>
          <description>Kaplan-Meier analysis of overall survival (Safety Population)</description>
          <population>Overall survival was assessed in the Safety Population (FLT3-ITD [-] participants).</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="12.0" upper_limit="29.4"/>
                    <measurement group_id="O2" value="25.1" lower_limit="18.1" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Treatment-related Death</title>
        <description>Early treatment-related deaths included all treatment-related deaths prior to the end of Cycle 3 with a 3-day window (Cycle 3 end date + 3 days), unless the death was following a CRc response assessed by the Investigator.</description>
        <time_frame>Within first 3 cycles of treatment (84 days)</time_frame>
        <population>Early treatment-related deaths were assessed in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1; ≥60 Years of Age</title>
            <description>Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory (N=24): FLT3-ITD(+): n=22; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=133): FLT3-ITD(+): n=90; FLT3-ITD(-): n=42; unknown: n=1
Total (N=157): FLT3-ITD (+): n=112; FLT3-ITD(-): n=44; unknown: n=1
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2; ≥18 Years of Age</title>
            <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory (N=38): FLT3-ITD(+): n=36; FLT3-ITD(-): n=2; unknown: n=0
Confirmatory (N=138): FLT3-ITD(+): n=100; FLT3-ITD(-): n=38; unknown: n=0
Total (N=176): FLT3-ITD(+): n=136; FLT3-ITD(-): n=40; unknown: n=0
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Treatment-related Death</title>
          <description>Early treatment-related deaths included all treatment-related deaths prior to the end of Cycle 3 with a 3-day window (Cycle 3 end date + 3 days), unless the death was following a CRc response assessed by the Investigator.</description>
          <population>Early treatment-related deaths were assessed in the Safety Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event (AE) data was collected after the first dose of study drug through 30 days after the last dose of study drug, approximately 5 years.</time_frame>
      <desc>Of note, AML disease progression (which includes the verbatim terms of progressive disease, disease progression, and relapsed AML) is reported as an AE in the data output and in the in-text tables; however, it is not considered an AE because of the population under study and is not further discussed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1; ≥60 Years of Age</title>
          <description>FLT3-ITD positive and negative populations will be divided into 2 cohorts as follows:
Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission &lt;12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2; ≥18 Years of Age</title>
          <description>Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Barrett's esophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Melena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Mouth hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease in skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Enterobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Escherichia bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Necrotizing fascitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pericoronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Serratia bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Vulval cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Accidental poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Endotracheal intubation complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Subdural hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Muscle hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Leukemic infiltration brain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lymphohistiocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Intraventricular hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Postictal state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute promyelocytic leukemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="157"/>
                <counts group_id="E2" events="48" subjects_affected="48" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="157"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="157"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="157"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="157"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="157"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="65" subjects_affected="65" subjects_at_risk="157"/>
                <counts group_id="E2" events="67" subjects_affected="67" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="157"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Mouth hemorrhage</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="85" subjects_affected="85" subjects_at_risk="157"/>
                <counts group_id="E2" events="89" subjects_affected="89" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="57" subjects_affected="57" subjects_at_risk="157"/>
                <counts group_id="E2" events="70" subjects_affected="70" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="157"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="157"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="157"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="157"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="157"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="157"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferse increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="157"/>
                <counts group_id="E2" events="48" subjects_affected="48" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="157"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="157"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="157"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="157"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="157"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="157"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="157"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="157"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="157"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="157"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="157"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="157"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="157"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="157"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dyspnea exertional</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="157"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="157"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hair color changes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="157"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="157"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daiichi Sankyo</name_or_title>
      <organization>Contact for Clinical Trial Information</organization>
      <phone>1-908-992-6400</phone>
      <email>CTRinfo@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

